Literature DB >> 8851619

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.

J E Hoppe1, E Rahimi-Galougahi, G Seibert.   

Abstract

The in vitro activities of levofloxacin, ofloxacin, d-ofloxacin, ciprofloxacin, cefpirome, and meropenem against 34 clinical isolates each of Bordetella pertussis and Bordetella parapertussis were determined by agar dilution on Mueller-Hinton agar supplemented with 5% horse blood. Levofloxacin was as active as ciprofloxacin against both species (MIC, 0.06 microgram/ml) and more active than ofloxacin and d-ofloxacin. Cefpirome was more active against B. pertussis (MIC, 1.0 microgram/ml) than against B. parapertussis (MIC, > 2 micrograms/ml), while the reverse was true for meropenem (MIC, 2.0 micrograms/ml against B. pertussis and 1.0 microgram/ml against B. parapertussis).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851619      PMCID: PMC163206     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.

Authors:  J E Hoppe; C G Simon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.

Authors:  J E Hoppe; A Eichhorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

3.  In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

Authors:  A Bauernfeind; S Schweighart; E Eberlein; R Jungwirth
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.

Authors:  N Dholakia; K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.

Authors:  M Asahara; A Tsuji; S Goto; K Masuda; A Kiuchi
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins.

Authors:  J E Hoppe; J Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  Penetration of cefpirome into sputum in chronic respiratory infections: comparison of administration of 0.5 g and 1.0 g in the same patient.

Authors:  H Shishido; H Nagai; S Miyake; T Kaburagi; K Satoh; K Deguchi
Journal:  Int J Clin Pharmacol Res       Date:  1993

8.  [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].

Authors:  Y Nakamori; E Tsuboi; K Narui; T Nakatani; K Nakata; H Sugi
Journal:  Jpn J Antibiot       Date:  1992-05

Review 9.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

10.  Concentration of meropenem in serum and in bronchial secretions in patients undergoing fibreoptic bronchoscopy.

Authors:  E Bergogne-Bérézin; C Muller-Serieys; M Aubier; M C Dombret
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more
  2 in total

Review 1.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

2.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.

Authors:  J E Hoppe; A Dalhoff; D Pfründer
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.